A novel LASSO-derived prognostic model predicting survival for non-small cell lung cancer patients with M1a diseases.

Our study established a nomogram for the prediction of 1- and 2-year OS in patients with NSCLC diagnosed with stage M1a, facilitating healthcare workers to accurately evaluate the individual survival of M1a NSCLC patients. The accuracy and clinical applicability of this nomogram were validated.